Evidence map›Paper›PMID 41473366›Full record

ArticleSouth Asian journal of cancer2025

Active Tuberculosis Risk Associated with Malignancies: A 4-Year Retrospective Study in a Tertiary Care Hospital.

Priyamvada Roy, Kiran Bala, Jaya Biswas, Javed Ahmed, Raunak Bir, Vishwanath Yadav, Ashit Xess, Sanjana Kumari, Prabhat Singh Malik, S V S Deo and 3 more

Abstract read
In one paragraph

Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Priyamvada RoyDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.ORCID 0000-0001-9139-134X
Kiran BalaDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Jaya BiswasDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Javed AhmedDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Raunak BirDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Vishwanath YadavDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Ashit XessDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Sanjana KumariDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Prabhat Singh MalikDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
S V S DeoDepartment of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Atul BatraDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Atul SharmaDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Urvashi B SinghDepartment of Microbiology, All India Institute of Medical Sciences, New Delhi, India.ORCID 0000-0001-8753-9743

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis (TB) remains an important public health problem worldwide. Risk of acquiring TB in patients diagnosed with cancers remains high and can result due to reactivation or reinfection. We share the experience in a large tertiary care hospital. Materials and Methods: Clinical samples from presumptive TB patients while on cancer therapy were tested by smear Ziehl-Neelsen (ZN) staining, GeneXpert MTB/RIF (Gx), TB polymerase chain reaction (PCR), and liquid culture (MGIT 960) from January 1, 2019, to December 31, 2022. Statistical Analysis: Stata 14.0 software was used for statistical analysis. The Results: Of 906 patients investigated, 42 (4.64%) tested positive for TB. Seven (1.37%) tested positive by ZN staining, 10 patients (6%) had culture positive by MGIT, 20 (10.53%) and 5 (13.51%) samples were positive by Gx and PCR, respectively. Maximum number of TB-positive patients were found to be suffering from carcinoma lung (28%) followed by leukemia (25%), gastrointestinal cancer (13%), and genitourinary cancer (13%), respectively. Seven of the 42 patients succumbed to the disease; the cases belonged to Hodgkin's lymphoma (75% mortality), leukemia (30% mortality), and genitourinary cancer (20% mortality). Conclusion: The incidence of active TB is high in cancer patients, especially lung cancer, leukemia, gastrointestinal, and genitourinary cancers. Mortality was high in Hodgkin's lymphoma patients who developed TB. Screening for TB at the time of diagnosis of a high TB risk cancer would help initiate early treatment. We recommend targeted screening for TB in patients with these high-risk cancers, at the time of diagnosis and periodically through cancer treatment.

Indexed as

GeneXpertlung cancerMGIT 960TB PCRZiehl–Neelsen stain

Identifiers

PMID41473366
PMCPMC12747770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.